[1]Santos AP, Gonçalves LC, Oliveira ACC, et al. Bacterial Co-Infection in Patients with COVID-19 Hospitalized (ICU and Not ICU): Review and Meta-Analysis. Antibiotics (Basel). 2022;11(7):894
[2]Brandi N, Ciccarese F, Balacchi C, et al. Co-Infections and Superinfections in COVID-19 Critically Ill Patients Are Associated with CT Imaging Abnormalities and the Worst Outcomes. Diagnostics (Basel). 2022;12(7):1617.
[3] Khongyot T, Moriyasu T. Invasive Pneumococcal Disease diminish during the onset of COVID-19 in Japan between 2019 and 2022. Int J Infect Dis. 2022;122:307-309. doi:10.1016/j.ijid.2022.05.064
[4] Danino D, Ben-Shimol S, van der Beek BA, et al. Decline in Pneumococcal Disease in Young Children During the Coronavirus Disease 2019 (COVID-19) Pandemic in Israel Associated With Suppression of Seasonal Respiratory Viruses, Despite Persistent Pneumococcal Carriage: A Prospective Cohort Study. Clin Infect Dis. 2022;75(1):e1154-e1164. doi:10.1093/cid/ciab1014
[5] Willen L, Ekinci E, Cuypers L, Theeten H, Desmet S. Infant Pneumococcal Carriage in Belgium Not Affected by COVID-19 Containment Measures. Front Cell Infect Microbiol. 2022;11:825427. Published 2022 Jan 17. doi:10.3389/fcimb.2021.825427
[6] Marta Bertran, Zahin Amin-Chowdhury, Carmen L,et al. Increased Incidence of Invasive Pneumococcal Disease among Children after COVID-19 Pandemic, England. Emerging Infectious Diseases.2022,28(8):1669-1672.
[7]https:///map/?set=number-of-cases-pneumonia&category=disease-burden&group=pneumococcal-cases
[8] 美国食品药品管理局. 已批准的疫苗产品.Prevnar 13 (肺炎球菌13价结合疫苗) [J/OL] http://www./BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm201667.htm.
[9] Nakashima K AM, Ohfuji S, et al. Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial[J]. Hum Vaccin Immunother, 2018,14(8): 1923- 1930.
[10] Ofori-Anyinam O L-RG, Drame M, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults >/=50years of age: Results from a phase III, randomized, non-inferiority trial[J]. Vaccine, 2017,35(46): 6321-6328.
[11] Marechal C LH, Poder A, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults >/=50years of age: A randomized trial[J]. Vaccine, 2018,36(29): 4278-4286.
[12] Agarwal N, Ollington K, Kaneshiro M, et al. Are immunosuppressive medications associated with decreased responses to routine immunizations? A systematic review[J]. Vaccine, 2012,30(8): 1413-1424.
[13] Kumar D, Welsh B, Siegal D, et al. Immunogenicity of pneumococcal vaccine in renal transplant recipients--three year follow-up of a randomized trial[J]. Am J Transplant, 2007,7(3): 633-638.